Mission and Vision
ROI
Return from pharma innovation
Deloitte has been publishing an annual report estimating the return on investment in pharmaceutical research and development. These reports show a long-term decline in productivity that reached 1.2% in 2022 before bouncing back to 4.1% in 2023. If this trend continues, the ROI will become negative around 2030.
Deloitte: Unleash AI’s potential Measuring the return from pharmaceutical innovation – 14th edition
Error rate
Error rate in lab-made plasmids.
The analysis of more than 2,500 plasmids provided by the clients of a contract research organization shows that more than half them have major problems. Some are poorly designed making them unlikely to achieve the intended function. Others do not match their published sequences.
Nature: Serious errors plague DNA tool that’s a workhorse of biology.
Waste
Annual U.S. Spending on Non-Reproducible
Preclinical Research
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US $28,000,000,000 (US$28B) per year spent on preclinical research that is not reproducible — in the United States alone.
PLOS: The Economics of Reproducibility in Preclinical Research
Reproducibility
Failure to reproduce results
More than 70% of researchers have tried and failed to reproduce another scientist's experiments, and more than half have failed to reproduce their own experiments.
Nature: More Than 1,500 Scientist Lift The Lid On Reproducibility
